English
新闻公告
More
化学进展 2013, Vol. 25 Issue (11): 1973-1980 DOI: 10.7536/PC130175 前一篇   后一篇

所属专题: 酶化学

• 综述与评论 •

双位点作用的乙酰胆碱酯酶抑制剂

郑伟1,3, 谢琼2, 陈良康1,3, 陈建兴1,3*, 仇缀百2*   

  1. 1. 上海市计划生育科学研究所 国家人口计生委重点实验室 上海 200032;
    2. 复旦大学药学院 上海 201203;
    3. 上海生殖健康药具工程技术研究中心 上海 200032
  • 收稿日期:2013-01-01 修回日期:2013-04-01 出版日期:2013-11-15 发布日期:2013-09-12
  • 通讯作者: 陈建兴, 仇缀百 E-mail:chenjx882002@aliyun.com;zbqiu@shmu.edu.cn
  • 基金资助:

    国家自然科学基金项目(No. 21202098)和上海市晨光计划项目(No.10CG03)资助

Dual Binding Site Acetylcholinesterase Inhibitors

Zheng Wei1,3, Xie Qiong2, Chen Liangkang1,3, Chen Jianxing1,3*, Qiu Zhuibai2*   

  1. 1. NPFPC Key Laboratory of Contraceptives and Devices Research, Shanghai Institute of Planned Parenthood Research, Shanghai 200032;
    2. School of Pharmacy, Fudan University, Shanghai 201203;
    3. Shanghai Engineer and Technology Research Center of Reproductive Health Drug and Devices, Shanghai 200032, China
  • Received:2013-01-01 Revised:2013-04-01 Online:2013-11-15 Published:2013-09-12

阿尔茨海默病(AD)是一种严重威胁老年人生命健康的疾病,在针对不同靶点的抗AD药物开发中,基于双位点作用的乙酰胆碱酯酶抑制剂的研究是当前热点领域。这类抑制剂不仅能提高患者脑内乙酰胆碱水平以改善其认知能力,同时可干扰Aβ的聚集,调控病理过程,从而发挥双重治疗AD的作用。本文综述了双位点作用的乙酰胆碱酯酶抑制剂的作用机理及近几年来已报道的先导化合物,同时结合本课题组开发的左旋美普他酚类双配基的研究结果,总结此类化合物的合理设计和构效关系,对双位点作用的乙酰胆碱酯酶抑制剂的药物开发中面临的一些挑战进行探讨,并对其发展趋势作了展望。

Alzheimer's disease (AD) is becoming a serious threat to life expectancy for elderly people. A hot area of treatments for AD is to develop dual binding site acetylcholinesterase (AChE) inhibitors that simultaneously interact with both the catalytic and peripheral anionic sites of the enzyme. These compounds may act as disease-modifying agents with multiple functions, not only improving cognition of AD patients by elevating acetylcholine levels, but also interfering with β-amyloid (Aβ) aggregation and delaying Aβ-elicited pathological process. Thus, the novel promising dual binding site AChE inhibitors reported in recent years are the focus of this review. Here, we first introduce the action mechanism of dual binding site AChE inhibitors, and then summarize the main classes of dimeric or hybrid compounds, along with the pharmacological profile of the most active candidates for AD therapy. In addition, combined with our preceding studies on (-)-meptazinol-based bivalents, the rational design strategy and structure-activity relationship of dual binding site AChE inhibitors are discussed. The current challenges and development trends are also proposed.

Contents
1 Introduction
2 The action mechanism of dual binding site AChEIs
3 Dual binding site AChE inhibitors
3.1 Homodimers
3.2 Heterodimers
3.3 Dual binding site AChEIs with additional functions
4 Conclusions and outlook

中图分类号: 

()

[1] Wimo A, Prince M. World Alzheimer Report 2010. Alzheimer's Disease International. (2010-09-21).[2011-06]. http://www. alz. co. uk/research/files/WorldAlzheimerReport2010. pdf
[2] Tayeb H O, Yang H D, Price B H, Taraz F I. Pharmacol. Therapeut., 2012, 134: 8—25
[3] Karran E, Mercken M, Strooper B D. Nat. Rev. Drug Discov., 2011, 10: 698—712
[4] Huang Y, Mucke L. Cell, 2012, 148: 1204—1222
[5] Sussman J L, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Science, 1991, 253: 872—879
[6] Johnson G, Moore S W. Curr. Pharm. Des., 2006, 12: 217—225
[7] Inestrosa N C, Dinamarca M C, Alvarez A. FEBS J., 2008, 275: 625—632
[8] Pang Y P, Quiram P, Jelacic T, Hong F, Brimijoin S. J. Biol. Chem., 1996, 271: 23646—23649
[9] Carlier P R, Han Y F, Chow E S H, Li C P L, Wang H, Lieu T X, Wong H S, Pang Y P. Bioorg. Med. Chem., 1999, 7: 351—357
[10] Muoz-Torrero D, Camps P. Curr. Med. Chem., 2006, 13: 399—422
[11] Nie H, Yu W J, Li X Y, Yuan C H, Pang Y P, Li C Y, Han Y F, Li Z W. Neurosci. Lett., 2007, 412: 108—113
[12] Correa-Basurto J, Flores-Sandoval C, Marín-Cruz J, Rojo-Domínguez A, Espinoza-Fonseca L M, Trujillo-Ferrara J G. Eur. J. Med. Chem., 2007, 42: 10—19
[13] Guillou C, Mary A, Renko D Z, Gras E, Thal C. Bioorg. Med. Chem. Lett., 2000, 10: 637—639
[14] Decker M. J. Med. Chem., 2006, 49: 5411—5413
[15] He X C, Feng S, Wang Z F, Shi Y, Zheng S, Xia Y, Jiang H, Tang X, Bai D. Bioorg. Med. Chem., 2007, 15: 1394—1408
[16] Wang R, Yan H, Tang X. Acta Pharmacol. Sin., 2006, 27: 1—26
[17] Haviv H, Wong D M, Greenblatt H M, Carlier P R, Pang Y P, Silman I, Sussman J L. J. Am. Chem. Soc., 2005, 127: 11029—11036
[18] Xie Q, Wang H, Xia Z, Lu M, Zhang W, Wang X, Fu W, Tang Y, Sheng W, Li W, Zhou W, Zhu X, Qiu Z, Chen H. J. Med. Chem., 2008, 51: 2027—2036
[19] Paz A, Xie Q, Greenblatt H M, Fu W, Tang Y, Silman I, Qiu Z, Sussman J L. J. Med. Chem., 2009, 52: 2543—2549
[20] Tumiatti V, Milelli A, Minarini A, Rosini M, Bolognesi M L, Micco M, Andrisano V, Bartolini M, Mancini F, Recanatini M, Cavalli A, Melchiorre C. J. Med. Chem., 2008, 51: 7308—7312
[21] Gemma S, Gabellieri E, Huleatt P, Fattorusso C, Borriello M, Catalanotti B, Butini S, Angelis M D, Novellino E, Nacci V, Belinskaya T, Saxena A, Campiani G. J. Med. Chem., 2006, 49: 3421—3425
[22] Alonso D, Dorronsoro I, Rubio L, Muňoz P, García-Palomero E, Monte M D, Bidon-Chanal A, Orozco M, Luque F J, Castro A, Medina M, Martínez A. Bioorg. Med. Chem., 2005, 13: 6588—6597
[23] Camps P, Formosa X, Munõz-Torrero D, Petrignet J, Badia A, Clos M V. J. Med. Chem., 2005, 48: 1701—1704
[24] Viayna E, Gómez T, Galdeano C, Ramírez L, Ratia M, Badia A, Clos M V, Verdaguer E, Junyent F, Camins A, Pallàs M, Bartolini M, Mancini F, Andrisano V, Arce M P, Rodríguez-Franco M I, Bidon-Chanal A, Luque F J, Camps P, Muñoz-Torrero D. ChemMedChem 2010, 5: 1855—1870
[25] Bolognesi M L, Andrisano V, Bartolini M, Banzi R, Melchiorre C. J. Med. Chem., 2005, 48: 24—27
[26] Belluti F, Piazzi L, Bisi A, Gobbi S, Bartolini M, Cavalli A, Valenti P, Rampa A. Eur. J. Med. Chem., 2009, 44: 1341—1348
[27] Belluti F, Bartolini M, Bottegoni G, Bisi A, Cavalli A, Andrisano V, Rampa A. Eur. J. Med. Chem., 2011, 46: 1682—1693
[28] Munõz-Ruiz P, Rubio L, García-Palomero E, Dorronsoro I, del Monte-Millán M, Valenzuela R, Usán P, de Austria C, Bartolini M, Andrisano V, Bidon-Chanal A, Orozco M, Luque F J, Medina M, Martínez A. J. Med. Chem., 2005, 48: 7223—7233
[29] Belluti F, Rampa A, Piazzi L, Bisi A, Gobbi S, Bartolini M, Andrisano V, Cavalli A, Recanatini M, Valenti P. J. Med. Chem., 2005, 48: 4444—4456
[30] Piazzi L, Belluti F, Bisi A, Gobbi S, Rizzo S, Bartolini M, Andrisano V, Recanatini M, Rampa A. Bioorg. Med. Chem., 2007, 15: 575—585
[31] Luo W, Li Y P, He Y, Huang S L, Tan J H, Ou T M, Li D, Gu L Q, Huang Z S. Bioorg. Med. Chem., 2011, 19: 763—770
[32] Mohamed T, Yeung J C K, Rao P P N. Bioorg. Med. Chem. Lett., 2011, 21: 5881—5887
[33] Tang H, Zhao L Z, Zhao H T, Huang S L, Zhong S M, Qin J K, Chen Z F, Huang Z S, Liang H. Eur. J. Med. Chem., 2011, 46: 4970—4979
[34] Tang H, Zhao H T, Zhong S M, Wang Z Y, Chen Z F, Liang H. Bioorg. Med. Chem. Lett., 2012, 22: 2257—2261
[35] Bareggi S R, Cornelli U. CNS Neurosci. Ther., 2012, 18: 41—46
[36] León R, Garcia A G, Marco-Contelles J. Med. Res. Rev., 2013, 33: 139—189
[37] Rosini M, Andrisano V, Bartolin M, Bolognesi M L, Hrelia P, Minarini A, Tarozzi A, Melchiorre C. J. Med. Chem., 2005, 48: 360—363
[38] Cavalli A, Bolognesi M L, Capsoni S, Andrisano V, Bartolini M, Margotti E, Cattaneo A, Recanatini M, Melchiorre C. Angew. Chem. Int. Ed., 2007, 46: 3689—3692
[39] Bolognesi M L, Cavalli A, Valgimigli L, Bartolini M, Rosini M, Andrisano V, Recanatini M, Melchiorre C. J. Med. Chem., 2007, 50: 6446—6449
[40] Rodríguez-Franco M I, Fernández-Bachiller M I, Pérez C, Hernández-Ledesma B, Bartolomé B. J. Med. Chem., 2006, 49: 459—462
[41] Fernández-Bachiller M I, Pérez C, Campillo N E, Páez J A, González-Munñoz G C, Usán P, García-Palomero E, López M G, Villarroya M, García A G, Martínez A, Rodríguez-Franco M I. ChemMedChem, 2009, 4: 828—841
[42] Fernández-Bachiller M I, Pérez C, González-Muñoz G C, Conde S, López M G, Villarroya M, García A G, Rodríguez-Franco M I. J. Med. Chem., 2010, 53: 4927—4937
[43] Fernaández-Bachiller M I, Pérez C, Monjas L, Rademann J, Rodríguez-Franco M I. J. Med. Chem., 2012, 55: 1303—1317
[44] Pisani L, Catto M, Giangreco I, Leonetti F, Nicolotti O, Stefanachi A, Cellamare S, Carotti A. ChemMedChem, 2010, 5: 1616—1630
[45] Alipour M, Khoobi M, Foroumadi A, Nadri H, Moradi A, Sakhteman A, Ghandi M, Shafiee A. Bioorg. Med. Chem., 2012, 20: 7214—7222
[46] Catto M, Pisani L, Leonetti F, Nicolotti O, Pesce P, Stefanachi A, Cellamare S, Carotti A. Bioorg. Med. Chem., 2013, 21: 146—152
[47] Zheng W, Li J, Qiu Z, Xia Z, Li W, Yu L, Chen H, Chen J, Chen Y, Hu Z, Zhou W, Shao B, Cui Y, Xie Q, Chen H. Toxicol. Appl. Pharmacol., 2012, 264: 65—72

[1] 蒋乔, 徐雪卉, 丁宝全. 纳米材料对生物凝聚态的调控[J]. 化学进展, 2020, 32(8): 1128-1139.
[2] 李高, 李艳梅. 截短与修饰的β-淀粉样蛋白与阿尔茨海默病[J]. 化学进展, 2020, 32(1): 14-22.
[3] 吕小平, 谭相石*. 阿尔茨海默病相关的金属内稳态平衡调控研究[J]. 化学进展, 2013, 25(04): 511-519.
[4] 刘琼,姜亮,田静,倪嘉缵. 硒蛋白的分子生物学及与疾病的关系*[J]. 化学进展, 2009, 21(05): 819-830.
[5] 陈祥纪. β-淀粉样斑块显像剂的研究*[J]. 化学进展, 2007, 19(01): 122-129.
[6] 张朝峰,杜会枝,杨频. 阿尔茨海默病分子机理的离子通道假说*[J]. 化学进展, 2006, 18(09): 1194-1199.
[7] 鄢浩,姜凤超. γ-分泌酶抑制剂研究进展[J]. 化学进展, 2006, 18(0203): 355-361.